Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs

Schizophrenia Bulletin

Volumn 29, Issue 1, 2003, Pages 81-93

  Rosenheck, Robert ^a,b,c   Doyle, Jefferson ^d   Leslie, Douglas ^b,c   Fontana, Alan ^e  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Northeast Program Evaluation Center   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e NONE

Author keywords

Cost effectiveness; Psychopharmacology veterans; Randomized controlled trials; Schizophrenia

Indexed keywords

BENZATROPINE MESILATE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AKATHISIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; ENVIRONMENTAL FACTOR; EVALUATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GOVERNMENT; HEALTH CARE COST; HEART PALPITATION; HOSPITAL PATIENT; HUMAN; HYPERSALIVATION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MENTAL PATIENT; OUTPATIENT; PATIENT CARE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOLDIER; STANDARD; TACHYCARDIA; VERTIGO; WEIGHT GAIN;

EID: 0038487333     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006994     Document Type: Review

References (38)

1. Barnes, T.R.E. A rating scale for drug-induced akathisia. British Journal of Psychiatry, 131:222-223, 1989.
2. Cramer, J.; Rosenheck, R.A.; and Charney, D.S. A comparison of instruments for the assessment of quality of life in schizophrenia. Schizophrenia Bulletin, 26(3):659-666, 2000.
3. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. Justice Expenditures and Employment in the United States, 1988. Publication No. NCJ-125619. Washington, DC: Government Printing Office, 1991a.
4. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. Sourcebook of Criminal Justice Statistics - 1990. Publication No. NCJ-130580. Washington, DC: Government Printing Office, 1991b.
5. Drug Topics Red Book. Montvale, NJ: Medical Economics Company, 1999.
6. Essock, S.M.; Frisman, L.K.; Covell, N.H.; and Hargreaves, W. Cost-effectiveness of clozapine compared with conventional antipsychotic medications for patients in state hospitals. Archives of General Psychiatry, 57(10):987-994, 2000.
7. Frisman, L.K., and Rosenheck, R.A. How transfer payments are treated in cost-effectiveness and cost-benefit analysis. Administration and Policy in Mental Health, 23:533-546, 1996.
8. Guy, W. Abnormal involuntary movements. In: Guy, W., ed. ECDEU Assessment Manual for Psychopharmacology. Department of Health, Education, and Welfare Publication No. ADM 76-338. Rockville, MD: National Institute of Mental Health, 1976a.
9. Guy, W. Clinical Global Impression. In: Guy, W., ed. ECDEU Assessment Manual for Psychopharmacology. Department of Health, Education, and Welfare Publication No. ADM 76-338. Rockville, MD: National Institute of Mental Health, 1976b.
10. Hayduk, L.A. Structural Equation Modelling With Lisrel. Baltimore, MD: Johns Hopkins University Press, 1987.
11. Heinrichs, D.W.; Hanlon, T.E.; and Carpenter, W.T. The Quality-of-Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 10(3):388-398, 1984.
12. Kane, J.; Honigfeld, G.; Singer, J.; and Meltzer, H. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45(9):789-796, 1988.
13. Kay, S.R.; Fiszbein, A.; and Opler, L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2):261-276, 1987.
14. Lehman, A. A quality of life interview for the chronically mentally ill. Evaluation and Program Planning, 11:51-62, 1988.
15. Leslie, D.L., and Rosenheck, R.A. Shifting to outpatient care? Mental health utilization and costs in a privately insured population. American Journal of Psychiatry, 156(8):1250-1257, 1999.
16. Leslie, D.L., and Rosenheck, R.A. The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia. Journal of Nervous and Mental Disease, 189(6):377-383, 2001a.
17. Leslie, D.L., and Rosenheck, R.A. The quality of pharmacotherapy for schizophrenia in a national healthcare system: Individual and facility predictors. Medical Care, 39(9):923-933, 2001b.
18. Leucht, S.; Pitschel-Walz, G.; Abraham, D.; and Kissling, W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials. Schizophrenia Research, 35(1):51-68, 1999.
19. Luchins, D.J.; Hanrahan, P.; Schinderman, M.; Lagios, L.; and Fichtner, C.G. Initiating clozapine treatment in the outpatient clinic: Service utilization and cost trends. Psychiatric Services, 49(8):1034-1038, 1998.
20. Meltzer, H.Y.; Burnett, S.; Bastani, B.; and Ramirez, L.F. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry, 41(8):892-897, 1990.
21. Office of the Inspector General. Comparison of Costs and Outcomes of Matched Pairs of VAMCs and Their University Affiliates. Washington, DC: Office of the Inspector General, 1992.
22. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale. Psychological Reports, 10:799-812, 1962.
23. Rosenheck, R.; Cramer, J.; Allan, E.; Erdos, J.; Frisman, L.; Xu, W.; Thomas, J.; Henderson, W.; and Charney, D. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Archives of General Psychiatry, 56(6):565-572, 1999.
24. Rosenheck, R.A.; Cramer, J.; Xu, W.; Thomas, J.; Henderson, W.; Frisman, K.; Fye, C.; and Chamey, D.; for the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. A comparison of clozapine and haloperidol in the treatment of hospitalized patients with refractory schizophrenia. New England Journal of Medicine, 337:809-815, 1997.
25. Rosenheck, R.A., and Greenberg, G. National Mental Health Program Performance Monitoring System: Fiscal Year 2001 Report. West Haven, CT: Northeast Program Evaluation Center, 2002.
26. Rosenheck, R.A., and Leslie, D. Economic perspectives on the treatment of schizophrenia. In: Murray, R., and Lieberman, J.A., eds. Comprehensive Care of Schizophrenia: A Textbook of Clinical Management. London, U.K.: Martin Dunitz, 2000. pp. 326-343.
27. Rosenheck, R.A.; Leslie, D.L.; and Semyak, M.E. From clinical trials to real-world practice: Use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Medical Care, 39(3):302-308, 2001.
28. Rosenheck, R.A.; Neale, M.; and Frisman, L. Issues in estimating the cost of innovative mental health programs. Psychiatric Quarterly, 66:9-31, 1995.
29. Rosenheck, R.A.; Tekell, J.; Peters, J.; Cramer, J.; Fontana, A.; Xu, W.; Thomas, J.; Henderson, W.; and Charney, D.; for the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Does participation in psychosocial treatment augment the benefit of clozapine? Archives of General Psychiatry, 55:618-625, 1998.
30. Rossi, P.H.; Freeman, H.E.; and Lipsey, M.W. Evaluation: A Systematic Approach. 5th ed. Newbury Park, CA: SAGE, 1993.
31. SAS Institute. SAS/STAT Software: CALIS and LOGISTIC Procedures. SAS Technical Report P-200. Cary, NC: SAS Institute, 1990.
32. Schneider, L.; Tariot, P.; Lyketsos, C.G.; Dagerman, K.S.; Davis, K.L.; Davis, S.; Hsiao, J.K.; Jeste, D.V.; Katz, I.R.; Olin, J.T.; Pollock, B.G.; Rabins, P.V.; Rosenheck, R.A.; Small, G.W.; Lebowitz, B.; and Lieberman, J.A. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. American Journal of Geriatric Psychiatry, 9:346-360, 2002.
33. Simpson, G.M., and Angus, J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, (Suppl):11-19, 1970.
34. Spitzer, R.S., and Endicott, J.E. The Semi-Structured Clinical Interview for Diagnosis. Washington, DC: American Psychiatric Press, 1990.
35. Tessler, R., and Gamache, G. Continuity of care, residence and family burden in Ohio. Milbank Quarterly, 72:149-169, 1994.
36. Tollefson, G.D., and Kuntz, A.J. Review of recent clinical studies with olanzapine. British Journal of Psychiatry, 37(Suppl):30-35, 1999.
37. U.S. General Accounting Office. Prescription Drugs: Expanding Access to Federal Prices Could Cause Other Price Changes. Publication No. GAO/HEHS-00-118. Washington, DC: U.S. GAO, 2000.
38. Weisbrod, B.; Test, M.A.; and Stein, L.I. Alternative to mental hospital treatment: II. Economic cost benefit analysis. Archives of General Psychiatry, 37:400-405, 1980.